FOSUN PHARMA Subsidiary's HLX3902 Injection Approved for Clinical Trials in Australia

Stock News17:04

FOSUN PHARMA announced that its subsidiary, Shanghai Henlius Biotech, Inc., along with its controlled subsidiaries, has received approval for the Phase I clinical trial protocol of its self-developed HLX3902 injection (a STEAP1xCD3xCD28 trispecific antibody) intended for the treatment of metastatic castration-resistant prostate cancer and other advanced solid tumors. The protocol has been approved by the relevant human research ethics committee and has passed the filing with Australia's Therapeutic Goods Administration. This marks the first global clinical trial approval for this drug candidate. Henlius plans to initiate the related clinical studies in Australia once the necessary conditions are met.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1181687396?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-21 17:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181687396","market":"sh","top_or_hot":-1,"title":"FOSUN PHARMA Subsidiary's HLX3902 Injection Approved for Clinical Trials in Australia","media":"Stock News","content":"<p>FOSUN PHARMA announced that its subsidiary, Shanghai Henlius Biotech, Inc., along with its controlled subsidiaries, has received approval for the Phase I clinical trial protocol of its self-developed HLX3902 injection (a STEAP1xCD3xCD28 trispecific antibody) intended for the treatment of metastatic castration-resistant prostate cancer and other advanced solid tumors. The protocol has been approved by the relevant human research ethics committee and has passed the filing with Australia's Therapeutic Goods Administration. This marks the first global clinical trial approval for this drug candidate. Henlius plans to initiate the related clinical studies in Australia once the necessary conditions are met.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FOSUN PHARMA Subsidiary's HLX3902 Injection Approved for Clinical Trials in Australia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFOSUN PHARMA Subsidiary's HLX3902 Injection Approved for Clinical Trials in Australia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-21 17:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FOSUN PHARMA announced that its subsidiary, Shanghai Henlius Biotech, Inc., along with its controlled subsidiaries, has received approval for the Phase I clinical trial protocol of its self-developed HLX3902 injection (a STEAP1xCD3xCD28 trispecific antibody) intended for the treatment of metastatic castration-resistant prostate cancer and other advanced solid tumors. The protocol has been approved by the relevant human research ethics committee and has passed the filing with Australia's Therapeutic Goods Administration. This marks the first global clinical trial approval for this drug candidate. Henlius plans to initiate the related clinical studies in Australia once the necessary conditions are met.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1181687396","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181687396","pubTimestamp":1779354280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"FOSUN PHARMA announced that its subsidiary, Shanghai Henlius Biotech, Inc., along with its controlled subsidiaries, has received approval for the Phase I clinical trial protocol of its self-developed...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK1191":"制药","BK1593":"医美概念股","BK0012":"证金概念","BK0188":"融资融券","BK1515":"抗疫概念","BK0196":"行业龙头","BK0175":"白马股","BK0060":"抗癌","BK0187":"一线龙头","02196":"复星医药","BK0028":"国家队","BK0239":"医药制造","BK0183":"MSCI概念","BK0096":"民营医院"},"translate_title":"复星医药子公司HLX3902注射液获批澳大利亚临床","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"FOSUN PHARMA announced that its subsidiary, Shanghai Henlius Biotech, Inc., along with its controlled subsidiaries, has received approval for the Phase I clinical trial protocol of its self-developed HLX3902 injection (a STEAP1xCD3xCD28 trispecific antibody) intended for the treatment of metastatic castration-resistant prostate cancer and other advanced solid tumors. The protocol has been approved by the relevant human research ethics committee and has passed the filing with Australia's Therapeutic Goods Administration. This marks the first global clinical trial approval for this drug candidate. Henlius plans to initiate the related clinical studies in Australia once the necessary conditions are met.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1181687396","isCrawlerRequest":true}